Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

Direct Biologics LLC announced that the FDA has approved the application for a Phase I/II trial under an Investigational New Drug (IND) protocol for the use of ExoFlo™ in the treatment of mild-to-moderate COVID-19. ExoFlo™ is an extracellular vesicle product isolated from human bone marrow MSCs.